CN1096856C - 局部治疗瘢痕组织的方法及对创伤的相关组织反应 - Google Patents
局部治疗瘢痕组织的方法及对创伤的相关组织反应 Download PDFInfo
- Publication number
- CN1096856C CN1096856C CN96193295A CN96193295A CN1096856C CN 1096856 C CN1096856 C CN 1096856C CN 96193295 A CN96193295 A CN 96193295A CN 96193295 A CN96193295 A CN 96193295A CN 1096856 C CN1096856 C CN 1096856C
- Authority
- CN
- China
- Prior art keywords
- application
- benzoyl peroxide
- scar tissue
- compositions
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 32
- 230000000699 topical effect Effects 0.000 title abstract description 5
- 238000000034 method Methods 0.000 title description 11
- 208000014674 injury Diseases 0.000 title 1
- 230000008733 trauma Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 30
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims description 10
- 239000002250 absorbent Substances 0.000 claims description 7
- 230000002745 absorbent Effects 0.000 claims description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 7
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 4
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 31
- 210000000589 cicatrix Anatomy 0.000 description 18
- 239000006210 lotion Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 210000001331 nose Anatomy 0.000 description 9
- 239000006071 cream Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- -1 Polyethylene Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000537 nasal bone Anatomy 0.000 description 1
- 229940032067 peg-20 stearate Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
局部施用于瘢痕组织部位的组合物,该组合物含通常用于化妆品的几种成分,例如过氧化苯甲酰,它可使瘢痕组织缩小并软化。
Description
发明背景
本发明涉及软化并缩小皮肤及皮下瘢痕组织的方法,具体说来,本发明涉及直接局部施用一种特定的组合物于瘢痕出现的身体部位(例如手术外伤引起的),治疗瘢痕组织的方法。
整型手术的进展,已使得由于外伤或手术介入造成的伤口,在皮肤层(上皮)和皮肤下面区域(皮下)出现瘢痕的问题得到改善。但是,到目前为止,在经过足够长时间,瘢痕块明显自然缩小停止之后,也没有什么办法可以使特定瘢痕组织外观正常化。
Schweiger的美国专利4694021(简称′021专利)披露一种具粘稠性的组合物,能使其凝固进出现瘢痕的区域,有利于瘢痕组织软化并缩小。该′021专利中,优选的组合物含有足够的水,尤其是要达到所希望的凝固稠度,即该稠度要保持到直至组合物干燥,硬化而凝固为止。实际上,该′021专利的优选市售产品是MUDD,因此,该组合物优选有面部包扎或面具的结构。因而,由局部施用该特定化合物治疗瘢痕组织的该方法,就其以笨大的面具形式敷用治疗剂的不便而论,证明其不切实际,和不会被广泛接受。于是有必要改进治疗瘢痕的方法,使之(1)施用容易且方便,(2)得到超常效果。
发明概述
因此本发明的目的是提供能有效地使瘢痕组织外观正常化的治疗瘢痕组织的治疗法,即使瘢痕块的自然缩小过程停止之后亦可行。
提供一种简单的、非侵害性的,相对廉价的软化和缩小皮肤及皮下瘢痕组织的方法,也是本发明之目的。
本发明的另一个目的是提供一种带有实用和舒适稠度、于软化和缩小皮肤和皮下瘢痕组织法中使用的化合物。
在达到前述目的时,根据本发明的一个方面,已提供了一种治疗瘢痕组织的方法,该方法包括将含过氧化苯甲酰、泥质吸收剂、及至少一种对羟基苯甲酸酯的治疗有效量之组合物,局部施用于出现皮肤和皮下瘢痕的身体部位之步骤。在一优选实施方案中,前述组合物敷于出现瘢痕的身体部位,其量足以使该组合物以薄层至中等厚度层之方式基本复盖整个受疤痕影响的身体部位。
此外,在一优选方案中,通过将含过氧化苯甲酰洗剂活性成分的组合物(下文中有时称之为优选组合物),反复以浅度涂敷或中度涂敷的方式敷于出现瘢痕的身体部位。该优选组合物的敷用方法是,以半分钟至1分钟时间将药敷好,然后将另一份组合物慢慢敷于前一层之上。该优选化合物的每次涂敷均轻微地复盖下面瘢痕影响的身体部位,使效果达极大值。对于鼻尖处的皮下瘢痕而言,该优选组合物也同样在两鼻翼上部的粘膜上涂以多层。
从下面的详细介绍,本发明的目的、特点和优点将变得显而易见。但应当清楚,当表明本发明优选实施方案时,仅仅是通过举例的方式给出详细介绍和具体实施例,因为从这些详细介绍,在本发明的精神和范围之内作出的变更和修改,对于本领域技术人员来说属显而易见。
发明详述
业已披露,一种已知在化妆品中使用,但并未确证其瘢痕块治疗效果的物质,可以通过局部施用产生缩小和软化瘢痕组织的效果,即使引起瘢痕的外伤已过了多年仍有效。虽然此种治疗效果的生理学基础并不清楚,但可以确信局部施用上述物质可诱导(或增长)瘢痕组织块中纤维物质脱钙或破碎的自然机理。该活性与下面的观测(下面将较详细介绍)一致,即局部施用本发明组合物,起到在鼻成型手术之后,皮肤及皮下瘢痕组织及钙化骨过生长的缩小作用。
本发明用于治疗瘢痕组织的组合物,优选含有泥质材料,例如固体硅酸铝,其既可作为吸收剂,又可作为组合物的基质。具体来说,优选用作吸收剂和组合物基质的硅酸铝是硅酸镁铝。
上述组合物还含有过氧化苯甲酰。过氧化苯甲酰用作面粉、脂肪、油和腊的漂白剂,以及用作不饱和油料的干燥剂。根据Hawley在Condensed Chemical Dictionary 120(Van Nostrand Co.1981)中记载,已有用过氧化苯甲酰作为药物及化妆品用不饱和油料的干燥剂使用,然而,并不知道影向瘢痕组织之作用是归因于过氧化苯甲酰的局部施用。
本发明组合物中的第三种成分是对羟基苯甲酸酯,例如对羟苯甲酸甲酯(Methyparaben)和对羟苯甲酸丙酯(Propylparaben)。此种酯广泛用于冷霜、眼睑膏、及液体化妆品中,作为防腐剂和杀微生物剂,但并不知道它们具有治疗活性。本发明中,优选对羟苯甲酸甲酯和丙酯均配入局部施用的组合物中。
遵循本发明所用组合物,也应含有皮肤清洁剂中所加一般成分,例如乳化剂,表面活性剂,稳定剂、溶剂等等,包括(但不限于)一硬脂酸甘油酯、棕榈酸异丙酯、聚乙二醇-(PEG)-20硬脂酸酯、丙二醇、硬脂酸、水、黄原胶和硬脂酸锌。
任何情况下,优选基本的含过氧化苯甲酰的组合物,大体上涂敷于瘢痕组织的整个部位,优选其量足以形成有效层。“大体上”一词,在本说明书上下文中,表示本发明之治疗,就效力而言,并不要求完全复盖瘢痕区域。但是,优选以轻微叠盖和涂层逐渐减弱透入未受影响的周围区域的方式而完全复盖瘢痕影响的身体部位。
也优选软化和缩小皮肤及皮下瘢痕组织之组合物,具有轻到中度重量和质地的稠度,因此能提供局部输送药物学有效量的优选组合物之有效而舒适的载体。
最后,本发明的用于治疗瘢痕组织的特别优选组合物含有10%过氧化苯甲酰洗剂(为KMart公司制造,Troy Michigan),即一种含前面所述10%过氧化苯甲酰,一硬脂酸甘油酯、棕榈酸异丙酯、硅酸镁铝、对羟苯甲酸甲酯、对羟苯甲酸丙酯、PEG-20硬脂酸酯,丙二醇、硬脂酸、水、黄原胶、及硬脂酸锌制剂的痤疮药剂。
周期性局部施用10%过氧化苯甲酰洗剂至主要由鼻成型手术或其它情况引起皮肤和皮下瘢痕的鼻部位,便同时产生瘢痕组织块缩小,伴随使保留下的瘢痕组织软化,以及明显使引起鼻骨加厚的钙过度增长减弱。
当10%过氧化苯甲酰洗剂(市售有助于治愈痤疮的制剂)被用于减轻在鼻翼细菌感染之目的时,本发明得以成功。治疗该细菌感染时,鼻尖部有多年前外科鼻成型术产生的瘢痕组织。用10%过氧化苯甲酰洗剂治疗感染四天之后,如预期的,不仅减弱了感染引起的不适,而且还使瘢痕组织缩小,且鼻尖外观变得更为正常,这是始料未及的结果。继续敷用10%过氧化苯甲酰洗剂,随后的几个月中,瘢痕组织继续缩小。此外,在尺寸减缩的同时瘢痕组织还得到软化。因为该产生被治疗瘢痕的外科手术是在17至18年前进行的,所以遵循本发明的该治疗效果,是尤其未曾预料到的,即该损伤组织的手术后明显正常化作用停止之后,取得了良好的治疗效果。
每次敷用10%过氧化苯甲酰洗剂治疗后的约1小时至1小时15分钟时,本发明可达最大效力。因当洗剂是湿的时候确信可出现最大效果,故对于施用优选组合物来说,相应于前述时间范围。将组合物分层敷用治疗,以确保洗剂不至于干得太快,而使得有利阶段缩短。治疗之后,用水将干残渣洗掉。轻涂非处方氢化可的松乳霜和/或润湿剂,可有助于预防或改善充血和脱皮现象。
如果10%过氧化苯甲酰洗剂的2-3次局部施用治疗相互贴近,一般间隔1-15分钟,可显示出倍增效应。此效应之结果,可以增加和/或加速瘢痕组织缩小,超过以相同次数治疗但间隔一天所得之结果。
另一可延长和/或增强本发明优选组合物治疗效果的改善技术是,在原始层涂敷之后25-35分钟,且第一次敷药仍是湿的时候,再以10%过氧化苯甲酰洗剂中度至重度涂敷。
任何情况下,如果在几分钟间隔时间进行二次或多次治疗,为有助于达到加速,提高,延长或增强效果,优选在优选组合物各次涂敷之前,尤其是后几次涂敷之前,轻抹非处方氢化可的松乳霜,和/或轻抹润湿剂洗液。此外,最后一层之后应优选涂抹氢化可的松乳霜及可能的一种润湿洗剂(与润湿乳霜不同,因为在一病例中,乳霜势必促使细菌感染),以免刺激被治疗部位。
以本发明的观点,确信过氧化苯甲酰是一种一般有助于身体修复自身,避免因组织损伤引起的过剩组织形成和液体产生的药物。所述损伤可由于外伤(即组织烧伤)产生,也可因关节炎之类的疾患而自然产生。因此,可断言,大量10%过氧化苯甲酰洗剂能缩短损伤治愈时间和持久性程度,并有助于脱钙及降低手关节炎畸型。此外,还声称可将适当的过氧化苯甲酰溶液注入关节的滑液组织,用于缓解关节炎问题。按此意向,适当的过氧化苯甲酰溶液在相关手术中使用是有效的。
但是,根据皮肤病学会诊结果,约有2%人口对10%过氧化苯甲酰过敏。因此,可以预料到,需要使用此种组合物软化和缩小皮肤及皮下瘢痕组织的人,在该组合物施用即刻,或随后的继续施用时,可产生过敏反应。结果可以引起单纯或隆突皮疹(一般情况)和/或轻度哮喘(皮肤病学会诊表明这种反应类型不太常见)。为此,由KMart公司销售的10%过氧化苯甲酰洗剂的说明书上,以“警告”指出:
仅供外用,若使用该产品同时,或紧随其后还用其它外用痤疮药剂,则可能加重皮肤干燥或刺激作用。若此情况发生,应只使用一种药剂,除非有医生指导。假如你的皮肤过敏,或者你对过氧化苯甲酰过敏,则不宜使用该药剂。该产品可能引起刺激作用,其特征是发红,灼烧感、痒、脱皮、或可能肿胀。若不过于频繁使用该产品,或使用较低浓度,便可减缓轻度刺激作用。若刺激变得严重,不要继续使用,如果刺激作用仍然不停,需找医生咨询。避免接触眼睛,嘴唇和口。如果意外吞食,则寻求专业救助,或立即与毒物控制中心联系。避免与头发、织物或地毯接触,因过氧化苯甲酰会引起漂白作用。
对于一贯皮肤过敏的人,可以在按常规施用10%过氧化苯甲酰洗剂之前,使用非处方1%氢化可的松乳霜,并用其后处理,以缓解发红及干燥症状。不管施用1%氢化可的松乳霜与否,均会使瘢痕组织软化和缩小。
上述发明已结合特别优选实施方案加以说明。本领域技术人员深知,可对本发明作出各种修改,而不至背离其精神和范围。
Claims (7)
1.治疗有效量的组合物在制备瘢痕组织治疗方法中使用的药物中的应用,所述组合物含下述成分之结合:(a)治疗有效量的过氧化苯甲酰,为活性成分,和(b)泥质吸收剂和至少一种对羟苯甲酸酯。
2.根据权利要求1的应用,其中所述吸收剂基本由硅酸铝组成。
3.根据权利要求2的应用,其中所述硅酸铝吸收剂基本上由硅酸镁铝组成。
4.根据权利要求1的应用,其中所述对羟苯甲酸酯是至少一种选自对羟苯甲酸甲酯和对羟苯甲酸丙酯的酯。
5.根据权利要求1的应用,其中所述组合物还含有一种或多种选自乳化剂,表面活性剂、稳定剂及溶剂的皮肤清洁佐剂。
6.根据权利要求1的应用,其中过氧化苯甲酰的含量为10%。
7.根据权利要求1的应用,其中所述组合物包含过氧化苯甲酰、泥质吸收剂、至少一种对羟苯甲酸酯、和一种或多种选自乳化剂、表面活性剂,稳定剂和溶剂的皮肤清洁佐剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39400095A | 1995-02-24 | 1995-02-24 | |
US08/394,000 | 1995-02-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1181698A CN1181698A (zh) | 1998-05-13 |
CN1096856C true CN1096856C (zh) | 2002-12-25 |
Family
ID=23557121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96193295A Expired - Fee Related CN1096856C (zh) | 1995-02-24 | 1996-02-23 | 局部治疗瘢痕组织的方法及对创伤的相关组织反应 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5789445A (zh) |
EP (1) | EP0820269A4 (zh) |
JP (1) | JPH11500730A (zh) |
CN (1) | CN1096856C (zh) |
AU (1) | AU709422B2 (zh) |
BR (1) | BR9607283A (zh) |
CA (1) | CA2213710A1 (zh) |
WO (1) | WO1996025912A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153888B2 (en) * | 2004-12-21 | 2006-12-26 | Alpharx Inc. | Stabilization of benzoyl peroxide in solution |
CA2600547A1 (en) * | 2005-03-10 | 2006-09-21 | Jr Chem, Llc | Benzoyl peroxide compositions and methods of use |
MX2007011048A (es) | 2005-03-10 | 2007-11-07 | Jr Chem Llc | Composiciones estables de peroxido organico. |
US7556820B2 (en) | 2005-06-29 | 2009-07-07 | Jr Chem, Llc | Stable organic peroxide compositions |
US20090306023A1 (en) * | 2005-06-29 | 2009-12-10 | Ramirez Jose E | Stable organic peroxide compositions |
US20070001145A1 (en) * | 2005-06-29 | 2007-01-04 | Faryniarz Joseph R | Stable organic peroxide compositions |
WO2007018846A2 (en) * | 2005-07-27 | 2007-02-15 | Pepgen Coporation | Use of interferon- tau for reduction of scar tissue formation |
US9511034B1 (en) | 2013-12-09 | 2016-12-06 | Bio-Silicote, Inc. | Method for applying a skin treatment |
CN115137867B (zh) * | 2022-04-26 | 2023-06-27 | 温州爱恩思生物科技有限公司 | 一种含有硅基无机材料的抗瘢痕材料及制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4189501A (en) * | 1977-10-07 | 1980-02-19 | A. H. C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4694021A (en) * | 1986-05-05 | 1987-09-15 | Schweiger Raymond H | Method for topical treatment of scar tissue |
US5047249A (en) * | 1988-07-22 | 1991-09-10 | John Morris Co., Inc. | Compositions and methods for treating skin conditions and promoting wound healing |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4056611A (en) * | 1973-04-16 | 1977-11-01 | Stiefel Laboratories, Inc. | Therapeutic composition |
DE3824247A1 (de) * | 1988-07-13 | 1990-01-18 | Schering Ag | Neue androstan-derivate |
-
1996
- 1996-02-23 EP EP96906462A patent/EP0820269A4/en not_active Ceased
- 1996-02-23 JP JP8525750A patent/JPH11500730A/ja not_active Ceased
- 1996-02-23 WO PCT/US1996/002066 patent/WO1996025912A1/en not_active Application Discontinuation
- 1996-02-23 CA CA002213710A patent/CA2213710A1/en not_active Abandoned
- 1996-02-23 AU AU49834/96A patent/AU709422B2/en not_active Ceased
- 1996-02-23 CN CN96193295A patent/CN1096856C/zh not_active Expired - Fee Related
- 1996-02-23 BR BR9607283A patent/BR9607283A/pt not_active Application Discontinuation
-
1997
- 1997-04-09 US US08/835,422 patent/US5789445A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4189501A (en) * | 1977-10-07 | 1980-02-19 | A. H. C. Pharmacal, Inc. | Composition and method for the treatment of acne |
US4694021A (en) * | 1986-05-05 | 1987-09-15 | Schweiger Raymond H | Method for topical treatment of scar tissue |
US5047249A (en) * | 1988-07-22 | 1991-09-10 | John Morris Co., Inc. | Compositions and methods for treating skin conditions and promoting wound healing |
Also Published As
Publication number | Publication date |
---|---|
EP0820269A4 (en) | 1999-06-30 |
EP0820269A1 (en) | 1998-01-28 |
JPH11500730A (ja) | 1999-01-19 |
MX9706453A (es) | 1998-07-31 |
US5789445A (en) | 1998-08-04 |
AU709422B2 (en) | 1999-08-26 |
WO1996025912A1 (en) | 1996-08-29 |
BR9607283A (pt) | 1998-12-15 |
CN1181698A (zh) | 1998-05-13 |
AU4983496A (en) | 1996-09-11 |
CA2213710A1 (en) | 1996-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3032481C2 (zh) | ||
US5583118A (en) | Method of treating an anorectal disease using hyaluronic acid-urea pharmaceutical compositions | |
EP2063859B1 (en) | Cosmetic composition for the treatment of skin and methods thereof | |
CA2595132A1 (en) | Agents for controlling biological fluids and methods of use thereof | |
Collins | The chemical peel | |
CA2105313A1 (en) | Therapeutic and cosmetic compositions for treatment of skin | |
CN1096856C (zh) | 局部治疗瘢痕组织的方法及对创伤的相关组织反应 | |
EP0531495B1 (en) | Therapeutic and cosmetic compositions for treatment of skin | |
KR20190013101A (ko) | 흉터의 예방 또는 치료를 위한 조성물 | |
RU2383341C2 (ru) | Способ омоложения кожи | |
CA2020017C (en) | Novel composition and topical and systemic treatments of conditions caused by heavy, oily or greasy secretions | |
WO1994015623A9 (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
Rubin | Trichloroacetic acid and other non-phenol peels | |
CN108379189A (zh) | 一种护肤霜及其制备方法 | |
Monheit | Combination medium-depth peeling: The Jessner's+ TCA peel | |
CN1053824C (zh) | 一种外用中药膏剂及其制备方法 | |
US4694021A (en) | Method for topical treatment of scar tissue | |
MXPA97006453A (en) | Compositions containing useful benzoyl peroxide in the topical treatment of scaled tissue and reaction to tissue trauma relationship | |
KR20080007962A (ko) | 시이트형 하이드로겔 팩의 조성물 및 그를 이용한 시이트형 하이드로겔 팩의 제조방법 | |
CN116942797A (zh) | 复合酸剥脱液及其制备方法 | |
RU2176536C1 (ru) | Способ лечения угревой болезни | |
CA1300505C (en) | Amelioration or elimination of postoperative pain | |
CN1104233C (zh) | 祛斑美容霜 | |
Frank et al. | Dermabrasion, Chemical Peel, and Collagen Injection | |
Komova | How to Treat Cold Sores after Lip Fillers in the Uk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |